West Pharmaceutical Services (NYSE:WST) Releases FY 2024 Earnings Guidance

West Pharmaceutical Services (NYSE:WST) issued an update on its FY 2024 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 6.350-6.650 for the period, compared to the consensus estimate of 7.740. The company issued revenue guidance of $2.9 billion-$2.9 billion, compared to the consensus revenue estimate of $3.0 billion.

West Pharmaceutical Services Stock Up 2.7 %

NYSE:WST opened at $284.76 on Friday. West Pharmaceutical Services has a 1-year low of $265.00 and a 1-year high of $415.73. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.61 and a quick ratio of 1.95. The firm’s 50-day moving average price is $324.09 and its 200-day moving average price is $355.79. The company has a market capitalization of $20.74 billion, a PE ratio of 37.57, a P/E/G ratio of 6.03 and a beta of 1.00.

West Pharmaceutical Services (NYSE:WST) last released its earnings results on Thursday, July 25th. The medical instruments supplier reported $1.52 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.74 by ($0.22). The business had revenue of $702.10 million for the quarter, compared to analysts’ expectations of $729.36 million. West Pharmaceutical Services had a net margin of 18.25% and a return on equity of 18.78%. West Pharmaceutical Services’s revenue for the quarter was down 6.9% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.11 earnings per share. On average, equities analysts predict that West Pharmaceutical Services will post 6.4 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, SVP Silji Abraham sold 1,800 shares of the firm’s stock in a transaction on Wednesday, June 12th. The stock was sold at an average price of $330.78, for a total transaction of $595,404.00. Following the completion of the transaction, the senior vice president now directly owns 2,860 shares in the company, valued at $946,030.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, CEO Eric Mark Green sold 66,000 shares of the stock in a transaction that occurred on Tuesday, May 7th. The shares were sold at an average price of $366.65, for a total transaction of $24,198,900.00. Following the sale, the chief executive officer now owns 152,908 shares in the company, valued at $56,063,718.20. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, SVP Silji Abraham sold 1,800 shares of the firm’s stock in a transaction that occurred on Wednesday, June 12th. The shares were sold at an average price of $330.78, for a total transaction of $595,404.00. Following the sale, the senior vice president now directly owns 2,860 shares of the company’s stock, valued at approximately $946,030.80. The disclosure for this sale can be found here. Corporate insiders own 0.53% of the company’s stock.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.